Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of MRG003 With PD-1 Induction Followed by Capecitabine and PD-1 Maintenance as First-line Treatment in Locally Recurrent Nasopharyngeal Carcinoma

NCT07331428 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT07331428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07331428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of MRG003 With PD-1 Induction Followed by Capecitabine and PD-1 Maintenance as First-line Treatment in Locally Recurrent Nasopharyngeal Carcinoma
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
December 31, 2029
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

local recurrence, nasopharyngeal carcinoma